EQT AB has agreed to acquire Qiagen NV for around €9.6 billion ($10.8 billion), bringing an end to years of takeover speculation involving the European molecular testing company.
Anonymous readers can preview up to 1024 characters here. Log in to unlock the full article once ingest succeeds.
